18F-FDG silicon photomultiplier PET/CT: A pilot study comparing semi-quantitative measurements with standard PET/CT

Baratto, Lucia; Park, Sonya Young; Hatami, Negin; Davidzon, Guido; Srinivas, Shyam; Gambhir, Sanjiv S.; Iagaru, Andrei

doi:10.1371/journal.pone.0178936

Cited by 46 publications

(38 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The high performance of the time-of-flight-enabled PET/MRI scanner (30) likely contributed to the identification of focal 68 Ga-RM2 uptake in structures of nonpathologically increased size but outside the expected physiologic 68 Ga-RM2 biodistribution. However, if there is no concern about pelvic recurrence, PET/CT is likely to yield results similar to PET/MRI with shorter imaging times, especially when using the recently introduced silicon-photomultiplier-based PET/CT scanners (42).…”

Section: Discussionmentioning

confidence: 99%

Prospective Evaluation of ⁶⁸Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Findings on Conventional Imaging

et al. 2017

Self Cite

View full text Add to dashboard Cite

Ga-labeled DOTA-4-amino-1-carboxymethyl-piperidine-d-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH (Ga-RM2) is a synthetic bombesin receptor antagonist that targets gastrin-releasing peptide receptor (GRPr). GRPr proteins are highly overexpressed in several human tumors, including prostate cancer (PCa). We present data from the use of Ga-RM2 in patients with biochemical recurrence (BCR) of PCa and negative findings on conventional imaging. We enrolled 32 men with BCR of PCa, who were 59-83 y old (mean ± SD, 68.7 ± 6.4 y). Imaging started at 40-69 min (mean, 50.5 ± 6.8 min) after injection of 133.2-151.7 MBq (mean, 140.6 ± 7.4 MBq) of Ga-RM2 using a time-of-flight-enabled simultaneous PET/MRI scanner. T1-weighted, T2-weighted, and diffusion-weighted images were acquired. All patients had a rising level of prostate-specific antigen (PSA) (range, 0.3-119.0 ng/mL; mean, 10.1 ± 21.3 ng/mL) and negative findings on conventional imaging (CT or MRI, and a Tc-methylene diphosphonate bone scan) before enrollment. The observedGa-RM2 PET detection rate was 71.8%. Ga-RM2 PET identified recurrent PCa in 23 of the 32 participants, whereas the simultaneous MRI scan identified findings compatible with recurrent PCa in 11 of the 32 patients. PSA velocity was 0.32 ± 0.59 ng/mL/y (range, 0.04-1.9 ng/mL/y) in patients with negative PET findings and 2.51 ± 2.16 ng/mL/y (range, 0.13-8.68 ng/mL/y) in patients with positive PET findings ( = 0.006). Ga-RM2 PET can be used for assessment of GRPr expression in patients with BCR of PCa. High uptake in multiple areas compatible with cancer lesions suggests thatGa-RM2 is a promising PET radiopharmaceutical for localization of disease in patients with BCR of PCa and negative findings on conventional imaging.

show abstract

Section: Discussionmentioning

confidence: 99%

Prospective Evaluation of ⁶⁸Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Findings on Conventional Imaging

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, recently, various studies using CT have been reported on pattern of differential diagnosis in cancer and other cases. [23][24][25][26][27][28][29] So we excluded the cases with tumoral thrombosis to excise this effect. Accordingly, using the vascular pattern within or around tumors improved differentiating accuracy of RCC from fat-poor AML than using morphologic criteria alone.…”

Section: Discussionmentioning

confidence: 99%

Tumoral vascular pattern in renal cell carcinoma and fat-poor renal angiomyolipoma as a novel helpful differentiating factor on contrast-enhanced CT scan

et al. 2017

View full text Add to dashboard Cite

Our objective was to evaluate the differences between tumoral vascular pattern of renal cell carcinoma and fat-poor angiomyolipoma by contrast-enhanced computed tomography. All included patients had a definitive pathological diagnosis of either angiomyolipoma or renal cell carcinoma, and then the contrast-enhanced computed tomography images of these patients were evaluated. The patients who had visible prominent vessels in cross-sectional imaging were selected. The tumor vascular pattern (prominent (>2 mm) intratumoral and peritumoral vessels), density, and diameter of the vessels in renal cell carcinoma and fat-poor angiomyolipoma were evaluated. All cases (n = 12) with fat-poor angiomyolipoma were found to have intratumoral vessels and all cases (n = 36) with clear cell renal cell carcinoma were found to have peritumoral vessels. There was no significant correlation detected between the diameter of tumor and the density as well as diameter of the vessels. In conclusion, the evaluation of the vascular pattern using contrast enhancement contrast-enhanced computed tomography may provide important information that is useful in helping accurate differential diagnosis of fat-poor angiomyolipoma or renal cell carcinoma preoperatively.

show abstract

“…The clinical study showed that the SUV mean was signi cantly higher using SiPM-PET than PMT-PET and did not correlate with the delay of the time from the injection (38). The superior spatial resolution by SiPM-PET not only improved image contrast but also increased the SUV mean in the cortex (39).…”

Section: Fovmentioning

confidence: 98%

Direct comparison of brain [18F]FDG images acquired by SiPM-based and PMT-based PET/CT: phantom and clinical studies

Wagatsuma

Sakata

Ishibashi

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Background: The silicon photomultiplier-positron emission tomography (SiPM-PET) developed by GE Healthcare has better sensitivity, spatial resolution, and timing resolution than photomultiplier tubes (PMT)-PET. The present study aimed to clarify the advantages of SiPM-PET in 18F-fluoro-2-deoxy-D-glucose ([18F]FDG) brain imaging in a head-to-head comparison with PMT-PET in phantom and clinical studies. Methods: Image contrast was calculated from images acquired from a Hoffman 3D brain phantom and image noise and uniformity were calculated from pooled images acquired from a pool phantom using SiPM- and PMT-PET. Sequential PMT-PET and SiPM-PET [18F]FDG images were acquired over a period of 10 min from 22 controls and 10 patients. All images were separately normalized to a standard [18F]FDG PET template, then mean standardized uptake values (SUVmean) and Z-score were calculated by MIMneuro and CortexID Suite, respectively. Results: Image contrast, image noise, and uniformity in SiPM-PET changed 19.2%, 3.5%, and -40.0% from PMT-PET, respectively. These physical indices of both PET scanners satisfied the criteria for acceptable image quality published by the Japanese Society of Nuclear Medicine of > 55%, ≤ 15% and ≤ 0.0249, respectively. The contrast in SiPM-PET was slightly improved using TOF. The SUVmean using SiPM-PET was significantly higher than PMT-PET and did not correlate with a time delay. Z-scores were also significantly higher in images acquired from SiPM-PET (except for the bilateral posterior cingulate) than PMT-PET because the peak signal that was extracted by the calculation of Z-score in CortexID Suite was raised. The area of hypometabolism in statistical maps was reduced and localized by SiPM-PET compared with PMT-PET regardless of whether the images were derived from controls or patients. Conclusions: The improved spatial resolution and sensitivity of SiPM-PET contributed to better image contrast and uniformity in brain [18F]FDG images. The SiPM-PET offers better quality and more accurate quantitation of brain PET images. The SUVmean and Z-score in SiPM-PET was higher than PMT-PET due to improving the PVEs. [18F]FDG images acquired using SiPM-PET will help to improve diagnostic outcomes based on statistical image analysis becausethe SiPM-PET would localize the distribution of glucose metabolism on Z-score maps.

show abstract

18F-FDG silicon photomultiplier PET/CT: A pilot study comparing semi-quantitative measurements with standard PET/CT

Cited by 46 publications

References 17 publications

Prospective Evaluation of ⁶⁸Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Findings on Conventional Imaging

Prospective Evaluation of ⁶⁸Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Findings on Conventional Imaging

Tumoral vascular pattern in renal cell carcinoma and fat-poor renal angiomyolipoma as a novel helpful differentiating factor on contrast-enhanced CT scan

Direct comparison of brain [18F]FDG images acquired by SiPM-based and PMT-based PET/CT: phantom and clinical studies

Contact Info

Product

Resources

About

18F-FDG silicon photomultiplier PET/CT: A pilot study comparing semi-quantitative measurements with standard PET/CT

Cited by 46 publications

References 17 publications

Prospective Evaluation of 68Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Findings on Conventional Imaging

Prospective Evaluation of 68Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Findings on Conventional Imaging

Tumoral vascular pattern in renal cell carcinoma and fat-poor renal angiomyolipoma as a novel helpful differentiating factor on contrast-enhanced CT scan

Direct comparison of brain [18F]FDG images acquired by SiPM-based and PMT-based PET/CT: phantom and clinical studies

Contact Info

Product

Resources

About

Prospective Evaluation of ⁶⁸Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Findings on Conventional Imaging

Prospective Evaluation of ⁶⁸Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Findings on Conventional Imaging